Karcinom dojke u trudnoći by Iva Andrašek et al.
83
REVIEW Libri Oncol. 2018;46(2-3):83–87
 doi: 10.20471/LO.2018.46.02-03.14
PREGNANCY ASSOCIATED BREAST CANCER
IVA ANDRAŠEK1, ILIJA ALVIR2 and LIDIJA BEKETIĆ-OREŠKOVIĆ1,3
1Division of Radiotherapy and Internal Medicine Oncology, University Hospital for Tumors, 
Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 
2Deptartment of Gynecologic Oncology Surgery, University Hospital for Tumors, 
Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 
3Department of Clinical Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia
Summary
Pregnancy-associated breast cancer is a diffi  cult psychosocial and health problem for the patient, demanding an indi-
vidual multidisciplinary treatment approach. Due to the need for aggressive oncological treatment with minimal adverse 
eff ects on the growing fetus, numerous studies are carried out to fi nd an optimal protocol, concerning the interest of both 
the mother and the child. Due to the physiological changes in the breasts in pregnancy, the diagnosis of breast cancer can be 
delayed and therefore patients have often higher clinical stage of the disease at initial presentation comparing to non-preg-
nant patients. Pregnancy termination due to breast cancer diagnosis had no eff ect on the prognosis of the patient, and long-
term studies did not fi nd a higher incidence of malignant disease in children who were exposed to chemotherapy in utero 
compared to the general population. Although prognosis data of those patients is controversial, recent studies have not 
found a worse outcome compared to breast cancer unrelated to pregnancy.
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KARCINOM DOJKE U TRUDNOĆI
Sažetak
Karcinom dojke povezan s trudnoćom teški je psihosocijalni i zdravstveni problem za pacijenticu i zahtjeva indivi-
dualni multidisciplinarni pristup liječenju. Zbog potrebe za agresivnim onkološkim liječenjem, uz minimalne štetne utje caje 
na rastući fetus, provode se brojne studije, čiji je zadatak pronaći optimalan protokol, vodeći se interesom i majke i djeteta. 
Zbog fi zioloških promjena dojke tijekom trudnoće, može doći do kašnjenja u postavljanju dijagnoze karcinoma dojke i 
 samim time višeg stadija bolesti pri inicijalnoj prezentaciji. Prekid trudnoće zbog dijagnoze karcinoma dojke nije mijenjao 
prognozu bolesti, a dugogodišnje studije nisu pokazale višu učestalost zloćudnih bolesti u djece intrauterino izložene kemo-
terapiji, u odnosu na opću populaciju. Iako su podaci o prognozi tih bolesnica kontroverzni, ipak većina novih studija nije 
ustanovila lošiji ishod u odnosu na bolesnice s karcinomom dojke nepovezanim sa trudnoćom.
KLJUČNE RIJEČI: trudnoća, karcinom dojke, terapija, prognoza
INTRODUCTION
Pregnancy-associated breast cancer (PABC) 
is defi ned as breast cancer diagnosed during preg-
nancy or in the fi rst postpartum year.
PABC is a major health problem for both the 
patient and the multidisciplinary team. Although 
the oncologic care is based on that of the non-
pregnant breast cancer patient, there are many 
challenges regarding the oncological and obstetri-
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cal aspects of care that need to be considered to 
deliver the best treatment plan for both the mother 
and the child.
Epidemiology
Breast cancer is one of the most common can-
cers diagnosed in pregnancy with the frequency 
approaching one in 3000 pregnancies (1). In wom-
en under the age of 30, up to 20 percent of breast 
cancers are pregnancy-associated, but only 5 per-
cent of breast cancers diagnosed in women young-
er than 50 are pregnancy related (2). Given that 
more women are delaying childbirth into their 
thirties and forties, the incidence of pregnancy-
related breast cancer is expected to rise.
There is evidence suggesting a transient in-
crease in breast cancer during the fi rst 3–4 years 
following pregnancy. A Norwegian population 
based study showed a short-term increase in 
breast cancer after full-term pregnancy, with a 
peak 3–4 years after the delivery (3).
Carriers of the BRCA1 and BRCA2 mutations 
have an increased risk of developing breast cancer 
in pregnancy, in fact, they are signifi cantly more 
likely to develop breast cancer by the age of 40 
than nulliparous carriers, with each pregnancy in-
creasing the risk (4).
Diagnosis
Breast cancer in pregnant patients is usually 
presented as a palpable mass (5). Most patients 
present with a painless palpable mass or breast 
skin thickening during breast feeding (6). Consid-
ering that, the fi rst obstetrical exam during preg-
nancy should include a thorough breast exam 
with encouragement of self-examinations through-
out the entire pregnancy and after delivery. Preg-
nancy-induced breast changes, such as enlarge-
ment, are thought to be some of the reasons of the 
delay of the diagnosis, and perhaps a poorer out-
come. In pregnancy, ultrasonography is a more 
suitable diagnostic procedure than mammogra-
phy and can help distinguish cystic and solid 
breast masses. If a biopsy is indicated by ultraso-
nography, further mammography must be per-
formed to identify the range of lesions, including 
microcalcifi cations. Mammograms can be per-
formed with the use of proper abdominal shield-
ing. Reported sensitivity of mammography ranges 
from 63-78%, owing to increased water content in 
the pregnant breast and loss of contrasting fat (7). 
The fi nding of a breast mass usually necessitates a 
biopsy or fi ne needle aspiration. It is necessary to 
inform the pathologist of the patient pregnancy 
because pregnant breast tissue is rapidly dividing 
and can be confused with rapidly dividing cancer 
cells.
Most studies have found that there are no 
major diff erences in the histology of breast cancer 
of pregnant and non-pregnant women (8). In 2012, 
Azim et al. published a case control study which 
included 65 patients diagnosed with breast cancer 
during pregnancy. They did not observe any sig-
nifi cant histological diff erences between pregnant 
and non-pregnant patients (9).
Treatment options
Current National Comprehensive Cancer 
Network guidelines recommend pregnancy ter-
mination upon diagnosis of breast cancer in the 
fi rst trimester of pregnancy. If the decision is con-
tinuation of pregnancy, the surgical procedure - 
mastectomy with axillary dissection is the prima-
ry recommendation during the fi rst trimester (10).
Depending on the pathohistological results, 
adjuvant chemotherapy should be administered 
after the end of the fi rst trimester. Most regimens 
use combinations of doxorubicin, cyclophospha-
mide and fl uorouracil. The use of weekly pacli-
taxel is considered acceptable if indicated by dis-
ease status. Selection of both local and systemic 
therapies are similar to those in non-pregnancy 
related breast cancer, however the timing diff ers. 
Adjuvant radiation therapy as well as hormone 
therapy should be reserved for the postpartum 
period, and chemotherapy should not be adminis-
tered before the second trimester. The use of blue 
dye is contraindicated during surgical approaches 
in pregnancy, radiolabeled sulfur colloid appears 
to be safer for sentinel node biopsy (10).
If breast cancer is diagnosed during the sec-
ond trimester or beginning of the third trimester, 
and the patient is a candidate, neoadjuvant che-
motherapeutic approach to treatment is also an 
option, followed by surgery and postpartum ra-
diation and endocrine therapy, depending on the 
indication (10).
Mastectomy or breast-conserving surgery 
with axillary staging is the recommended option 
for tumors diagnosed in the late third trimester, 
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with adjuvant chemotherapy, postpartum radia-
tion and endocrine therapy, depending on the 
pathohistological results, (10).
Data suggest that one third of pregnant breast 
cancer patient have Her-2 positive disease (11). 
However, one study has shown that application of 
trastuzumab during pregnancy increases the risk 
of oligohydramnios and anhydramnios and should 
not be recommended until postpartum (12). A re-
cently published case report showed fetal growth 
retardation, oligohydramnios and right renal 
agenesis in a patient who became pregnant while 
receiving trastuzumab and pertuzumab for meta-
static breast cancer, resulting in pregnancy termi-
nation (13).
Tamoxifen is a non-steroidal estrogen with 
both agonist and antagonist activity. The use of 
tamoxifen is not recommended during pregnancy, 
since tamoxifen and its metabolites interact with 
rapidly growing and developing embryonic or fe-
tal tissues, resulting in a relatively high frequency 
of severe congenital anomalies such as ambiguous 
genitalia (14, 15).
Although chemotherapy is considered safe 
after the fi rst trimester, only few studies have in-
vestigated the long-term eff ect of in utero expo-
sure. Some chemotherapeutic agents are known to 
cross the placental barrier such as cisplatin (16), 
cyclophosphamide (17), doxorubicine (18) and 
methotrexate (19). Methotrexate has been associ-
ated with malformations of the central nervous 
system, skeletal, gastrointestinal, and cardiac mal-
formations, and even fetal death (20).
In a review of 43 pregnant women given plat-
inum-based chemotherapy, detectable cisplatin 
concentrations or platinum-DNA adducts were 
found in neonates who had been exposed to plati-
num derivatives during the third trimester (21). 
Recent studies have shown a relationship between 
platinum-based chemotherapy and fetuses small 
for gestational age (22). The long latent period of 
some cancers remains a problem for accurate risk 
identifi cation.
Fetal outcome
There is no evidence that early termination of 
pregnancy improves prognosis. The decision to 
terminate pregnancy is, to a large extent, a per-
sonal choice of the woman or the couple, follow-
ing extensive discussions with a multidisciplinary 
team (23).
Since pregnancy-associated breast cancer is a 
relatively rare disease, only few studies have inves-
tigated short and long-term eff ects of in utero fetal 
exposure to chemotherapy. An observational study 
which included 447 pregnant patients, 413 of whom 
had early breast cancer showed that even though 
infants exposed to chemotherapy in utero had a 
lower birthweight and more complications, these 
diff erences were not clinically signifi cant and, since 
none of them was exposed to chemotherapy in the 
fi rst trimester, were most likely related to prema-
ture delivery. A full-term delivery seems to be of 
outmost importance, since preterm birth was 
strongly associated to adverse events (24).
A recently published study on 81 pregnant 
patients being treated with anthracycline-based 
chemotherapy for breast cancer between 1992 and 
2010 found no trend to indicate a higher rate of 
serious medical problems in the children of these 
patients, who were exposed to chemotherapy in 
utero, than that seen in the general population. 
Therefore it seems reasonable to conclude that 
treating breast cancer during the second and third 
trimesters with anthracycline-based chemothera-
py does not jeopardize the outcome of the devel-
oping fetus (25, 26).
Lactation is contraindicated during chemo-
therapy, and if milk secretion is maintained 
throughout chemotherapy, breastfeeding can be 
allowed 3–4 weeks after the last administered 
dose of chemotherapy, since all chemotherapeu-
tics have been detected in breast milk. Tissue fi -
brosis as a result of radiotherapy may inhibit lac-
tation on the aff ected side in the future (27).
Prognosis
The prognosis of breast cancer in pregnant 
patients remains controversial. A recent retrospec-
tive study found no signifi cant diff erences in over-
all survival, disease-free survival or distant recur-
rence rates between pregnant and non-pregnant 
breast cancer patients. Pregnancy associated sta-
tus, a primary tumor larger than 5 cm and neoad-
juvant chemotherapy as the primary treatment 
were signifi cantly associated with an increased 
risk of local relapse. Interestingly, although preg-
nant patients have more locally advanced tumors, 
they did not have a higher rate of radical surgery 
than the control breast cancer group. Pregnancy 
associated status is a strong prognostic factor of 
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local relapse in breast cancer, so authors recom-
mend, when possible, radical surgery as the fi rst 
treatment step (28, 29).
Conclusion
Considering the trend to postpone childbear-
ing and the general increase in the incidence of 
breast cancer, the incidence of pregnancy-associ-
ated breast cancer is expected to increase. An indi-
vidual multidisciplinary approach is needed for 
this diffi  cult psychosocial and health problem. 
Treatment of pregnancy-associated breast cancer 
should follow the guidelines for non-pregnant pa-
tients as close as possible. Evidence suggest the 
safety of administration of certain chemotherapy 
after the fi rst trimester of pregnancy. Radiothera-
py, trastuzumab and antihormonal treatment are 
contraindicated during pregnancy. Pregnancy 
does not seem to worsen the prognosis of breast 
cancer patients. Most fetal complications are re-
lated to preterm delivery, which should therefore 
be avoided whenever is possible.
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